drugset / Trial / NCT06414499
Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of intravenous tenecteplase (0.25 mg/kg) compared with standard therapy in patients with acute ischemic stroke presenting with mild symptoms-defined as a National Institutes of Health Stroke Scale (NIHSS) score ≤5 accompanied by persistent unilateral limb weakness or speech impairment within 4.5 hours of onset.
Timeline
- Start
- 2025-07-09
- Primary completion
- 2026-07-31
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | 100 mg | — |
| Comparator | Clopidogrel | Small molecule | 300 mg | — |
| Subject | Tenecteplase | Protein / enzyme biologic | 0.25 mg/kg | Intravenous |